268 related articles for article (PubMed ID: 30264546)
1. Mechanism and prognostic value of indoleamine 2,3-dioxygenase 1 expressed in hepatocellular carcinoma.
Li S; Han X; Lyu N; Xie Q; Deng H; Mu L; Pan T; Huang X; Wang X; Shi Y; Zhao M
Cancer Sci; 2018 Dec; 109(12):3726-3736. PubMed ID: 30264546
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.
Zhou QH; Han H; Lu JB; Liu TY; Huang KB; Deng CZ; Li ZS; Chen JP; Yao K; Qin ZK; Liu ZW; Li YH; Guo SJ; Ye YL; Zhou FJ; Liu RY
Cancer Commun (Lond); 2020 Jan; 40(1):3-15. PubMed ID: 32125093
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of tumour-infiltrating CD8+ lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?
Schollbach J; Kircher S; Wiegering A; Seyfried F; Klein I; Rosenwald A; Germer CT; Löb S
Cancer Immunol Immunother; 2019 Apr; 68(4):563-575. PubMed ID: 30671614
[TBL] [Abstract][Full Text] [Related]
4. Tumoral indoleamine 2, 3-dioxygenase 1 is regulated by monocytes and T lymphocytes collaboration in hepatocellular carcinoma.
Zhao Q; Wang PP; Huang ZL; Peng L; Lin C; Gao Z; Su S
Oncotarget; 2016 Mar; 7(12):14781-90. PubMed ID: 26895379
[TBL] [Abstract][Full Text] [Related]
5. Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma.
Zhou S; Yang H; Zhang J; Wang J; Liang Z; Liu S; Li Y; Pan Y; Zhao L; Xi M
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):286-294. PubMed ID: 32004580
[TBL] [Abstract][Full Text] [Related]
6. Effects of upregulated indoleamine 2, 3-dioxygenase 1 by interferon γ gene transfer on interferon γ-mediated antitumor activity.
Watcharanurak K; Zang L; Nishikawa M; Yoshinaga K; Yamamoto Y; Takahashi Y; Ando M; Saito K; Watanabe Y; Takakura Y
Gene Ther; 2014 Sep; 21(9):794-801. PubMed ID: 24919418
[TBL] [Abstract][Full Text] [Related]
7. Identification of an IDO1-based immune classifier for survival prediction of upper tract urothelial carcinoma.
Zhong W; Yang M; Cheng S; Hou W; Wang B; Chen J; Yu H; Ouyang Y; Wang X; Ou Z; Xu P; Li X; Zhou L; Huang J; Wang C; Lin T
Cancer Sci; 2022 Mar; 113(3):852-863. PubMed ID: 34962030
[TBL] [Abstract][Full Text] [Related]
8. Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma.
Liang X; Gao H; Xiao J; Han S; He J; Yuan R; Yang S; Yao C
Front Immunol; 2023; 14():1185985. PubMed ID: 37334368
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine-2,3-dioxygenase-1 expression predicts poorer survival and up-regulates ZEB2 expression in human early stage bladder cancer.
Tsai YS; Jou YC; Tsai HT; Cheong IS; Tzai TS
Urol Oncol; 2019 Nov; 37(11):810.e17-810.e27. PubMed ID: 31253481
[TBL] [Abstract][Full Text] [Related]
10. Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration.
Liu XQ; Lu K; Feng LL; Ding M; Gao JM; Ge XL; Wang X
Leuk Lymphoma; 2014 Feb; 55(2):405-14. PubMed ID: 23682557
[TBL] [Abstract][Full Text] [Related]
11. H
Yang D; Li T; Li Y; Zhang S; Li W; Liang H; Xing Z; Du L; He J; Kuang C; Yang Q
J Exp Clin Cancer Res; 2019 Feb; 38(1):88. PubMed ID: 30777103
[TBL] [Abstract][Full Text] [Related]
12. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
13. Aberrant Upregulation of Indoleamine 2,3-Dioxygenase 1 Promotes Proliferation and Metastasis of Hepatocellular Carcinoma Cells via Coordinated Activation of AhR and β-Catenin Signaling.
Chen CT; Wu PH; Hu CC; Nien HC; Wang JT; Sheu JC; Chow LP
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769098
[TBL] [Abstract][Full Text] [Related]
14. Targeting Lin28 axis enhances glypican-3-CAR T cell efficacy against hepatic tumor initiating cell population.
Patra T; Cunningham DM; Meyer K; Toth K; Ray RB; Heczey A; Ray R
Mol Ther; 2023 Mar; 31(3):715-728. PubMed ID: 36609146
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma.
Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q
BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238
[TBL] [Abstract][Full Text] [Related]
16. Increased mRNA expression of chemokines in hepatocellular carcinoma with tumor-infiltrating lymphocytes.
Hirano S; Iwashita Y; Sasaki A; Kai S; Ohta M; Kitano S
J Gastroenterol Hepatol; 2007 May; 22(5):690-6. PubMed ID: 17444857
[TBL] [Abstract][Full Text] [Related]
17. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma.
Huang CY; Wang Y; Luo GY; Han F; Li YQ; Zhou ZG; Xu GL
J Immunother; 2017; 40(9):323-333. PubMed ID: 29028787
[TBL] [Abstract][Full Text] [Related]
18. Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma.
Pan K; Wang H; Chen MS; Zhang HK; Weng DS; Zhou J; Huang W; Li JJ; Song HF; Xia JC
J Cancer Res Clin Oncol; 2008 Nov; 134(11):1247-53. PubMed ID: 18438685
[TBL] [Abstract][Full Text] [Related]
19. Effects of gene silencing of indoleamine 2,3-dioxygenase 1 combined with rosmarinic acid on tumor immune microenvironment in H22 tumor-bearing mice.
Cao W; Pan J; Mo K; Wang Z; Wei S; Yin Y; Qin M; Zhang W
Int Immunopharmacol; 2023 Jun; 119():110193. PubMed ID: 37062258
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon γ signature.
Sailer V; Sailer U; Bawden EG; Zarbl R; Wiek C; Vogt TJ; Dietrich J; Loick S; Grünwald I; Toma M; Golletz C; Gerstner A; Kristiansen G; Bootz F; Scheckenbach K; Landsberg J; Dietrich D
EBioMedicine; 2019 Oct; 48():341-352. PubMed ID: 31628024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
